Skip to main content

Table 4 Patient characteristics of the study population in the 4th supplementary analysis

From: Impact of the interval between neoadjuvant concurrent chemoradiotherapy and esophagectomy in the modern era: a population-based propensity-score-matched retrospective cohort study in Asia

 

Short interval (n = 63)

Long interval (n = 63)

 

Number or

mean (sd)

(%)

Number or

mean (sd)

(%)

SDif

Age

 

54.17 (8.22)

 

54.46 (8.63)

 

0.034

Gender

Female

0

Male

 

Residency

Non-north

43

(68)

39

(62)

0.133

North

20

(32)

24

(38)

 

Tumor size

≤ 5 cm

17

(27)

20

(32)

0.105

> 5 cm

46

(73)

43

(68)

 

Tumor differentiation

Poorly/undifferentiated

14

(22)

18

(29)

0.146

Well/moderately

49

(78)

45

(71)

 

RT delivery

Non-IGRT

51

(81)

53

(84)

0.084

IGRT

12

(19)

10

(16)

 

Use of PET

No

9

(14)

8

(13)

0.046

Yes

54

(86)

55

(87)

 

Tumor location

Cervical

0

Non-cervical

 

T-stage

T1–T2

8

(13)

8

(13)

0

T3–T4

55

(87)

55

(87)

 

N-stage

Negative

6

(10)

6

(10)

0

Positive

57

(90)

57

(90)

 

Drinking

No

8

(13)

8

(13)

0

Yes

55

(87)

55

(87)

 

Betel nut chewing

No

27

(43)

27

(43)

0

Yes

36

(57)

36

(57)

 

Smoking

No

10

(16)

9

(14)

0.044

Yes

53

(84)

54

(86)

 

BMI

 

21.84 (3.40)

 

22.07 (3.39)

 

0.07

Number of LNs

< 15

12

(19)

15

(24)

0.116

≥ 15

51

(81)

48

(76)

 

RT dose (Gy)

 

48.30 (3.47)

 

47.59 (3.54)

 

0.205

Patient volume

Low volume

23

(37)

20

(32)

0.101

High volume

40

(63)

43

(68)

 

Positive LN

 

0.70 (1.29)

 

0.75 (1.75)

 

0.031

  1. BMI body mass index, IGRT image-guided radiotherapy, LN lymph node, nCCRT neoadjuvant concurrent chemoradiotherapy, PET positron emission tomography, RT radiotherapy, sd standard deviation, SDif standardized difference
  2. Rounded
  3. The exact numbers were not reported because of a Health and Welfare Data Science Center (HWDC) database center policy to avoid numbers in single cells (≤ 2)